Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: J Vasc Surg. 2014 Oct 24;63(3):795–804. doi: 10.1016/j.jvs.2014.09.036

Figure 1.

Figure 1

Ephrin-B2/Fc reduces neointimal thickness in human saphenous vein organ culture. A-C) Representative photomicrographs of (A) saphenous vein at day 0, or the same vein after 14 days in organ culture and either (B) control or (C) treated with Ephrin-B2/Fc (2 μg/ml); elastin von Gieson stain. Scale bar, 100 μm. D) Bar graph shows mean neointima:media ratio for vein rings, day 0 or 14, matched samples treated without or with Ephrin-B2/Fc. n=19. *, p=0.001; **, p=0.048 vs. day 0; **, p=0.017 vs. day 14 untreated; paired t-test. E) Graph shows the neointima:media ratio in matched vein segments after 14 days. F) Bar graph shows proportion of Ki-67 positive nuclei in vein rings after 3 days in organ culture. p=0.396, day 3 untreated vs. day 0; p=0.798, day 3 treated vs. day 0; p=0.384, day 3 untreated vs. treated; paired t-test. n=3. G) Bar graph shows densitometry of Western blot analysis of cleaved caspase-3 expression, normalized to GAPDH, in vein rings, day 0 or 3. p=0.079, day 3 untreated vs. day 0; p=0.055, day 3 treated vs. day 0; p=0.827, day 3 untreated vs. treated; paired t-test. n=3. AU, arbitrary units.